Ultrarapid BRAF mutation detection on supernatant cell‐free DNA obtained by FNA: An accurate and expedient method for BRAF assessment in aggressive thyroid carcinomas

For patients with aggressive thyroid cancer, including anaplastic thyroid carcinoma (ATC) and high‐grade follicular cell‐derived non‐anaplastic thyroid carcinoma, rapid BRAF p.V600E testing is critical as targeted therapy with BRAF/MEK inhibitors significantly improves outcomes. This study assesses the performance and turnaround time (TAT) of the Biocartis Idylla platform for ultrarapid BRAF p.V600E detection across various preparations, emphasizing the use of residual CytoLyt material (supernatant cell‐free DNA [ScfDNA]).